| 杨丽 (2010)12) | 52(26/26);T:9/17; 38.65±10.881; NRC:8/18; 34.81±10.450; NR | 1.CHM(ultrasonic inhalation, tid) | 1.distilled water(ultrasonic inhalation, tid) | 1.VAS2.MTT | 7d | No adverse events |
| 王爱民 (2010)13) | 210(70/70/70);N:76/134; 6.8;4wk-3.5yr | T1 : 1.Xoingdan Tongbi(nasal spray, bid) plus CT2: 1.Fluticasone propionate (nasal spray, bid) plus C | 1.pharmacotherapy (oral) | 1.Effective rate | 2wk | NR |
| 苏应东 (2012)14) | 496(250/246);N:215/281; 30;1-22yr | 1.CHM(ultrasonic inhalation, bid) | 1.Fangzhi Biyan Pian (oral, tid) | 1.Effective rate | 10d | NR |
| 王刚 (2013)15) | 98(49/49); NR;10.4±2.6; ≥3mon | 1.Ma yi bi yan spray(nasal spray, tid) plus C | 1.cefuroxime or roxithromycin | 1.Effective rate2.VAS3.SNOT-204.Lund-Kennedy | 20d | NR |
| 唐思晨 (2019)16) | 72(36/36);T:12/24; 35.5±10.4; 7.7±3.2monC:15/21; 36.3±10.3; 7.8±2.9mon | 1.Longdan Xiegan Decoction (fumigation, bid) | 1.nomal saline (fumigation, bid) | 1.Effective rate2.VAS3.MTR | 28d | No adverse events |
| 吴紫陆 (2021)17) | 168(84/84);T:43/41; 8.28±1.76; 5.40±0.94monC:39/45; 9.62±2.19;5.21±1.13mon | 1.Bikangfu(nasal administration, qd) | 1.Tongqiao Biyan granules(oral, tid)2.Sinupret® (oral, tid) | 1.Effective rate2.VAS3.Lund-Mackay4.Symptom score5.Levels of inflammatory factors in serum and nasal secretions | NR | Mild rashes: T(0), C(2) |
| 毛新桐 (2021)18) | 60(30/30);T:13/17; 39.83±14.61; 2.30±1.99yrC:16/14; 38.60±12.92; 1.66±1.23yr | 1.Shenlingbaizhu Powder(oral, bid)2.Shenlingbaizhu Powder(steam inhalation, bid) | 1.Shenlingbaizhu Powder(oral, bid)2.water(steam inhalation, bid) | 1.Lund-Kennedy2.Symptom score | NR | NR |
| 艾斌 (2021)19) | 220(110/110);T:54/56; 39.15±1.46; NRC:55/55; 39.57±1.37; NR | 1.Cang er zi san modified(ultrasonic inhalation, qd) | 1.budesonide (nasal spray, bid)2.roxithromycin (oral, bid) | 1.Effective rate | 4wk | NR |